Evidence map›Paper›PMID 30127358›Full record

ArticleNature structural & molecular biology2018

Structural determinants of 5-HT

John D McCorvy, Daniel Wacker, Sheng Wang, Bemnat Agegnehu, Jing Liu, Katherine Lansu, Alexandra R Tribo, Reid H J Olsen, Tao Che, Jian Jin and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 170 citations in OpenAlex.

  1. Deciphering the allosteric landscape of 5-HTPharmacological reports : PR · 2026
    Article
  2. Mechanistic Basis for 5-HTNature communications · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Biased Signaling in Psychedelic Action.Annual review of pharmacology and toxicology · 2026
    Review
  12. Review
  13. Article
  14. Discovery of Highly Selective 5-HTJournal of medicinal chemistry · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. De novo design of a fusion protein tool for GPCR research.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  19. 5-HTPharmacological reviews · 2025
    Review
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

John D McCorvyNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA. jmccorvy@mcw.edu.ORCID http://orcid.org/0000-0001-7555-9413
Daniel WackerNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA.
Sheng WangNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0003-4176-8844
Bemnat AgegnehuNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA.
Jing LiuCenter for Chemical Biology and Drug Discovery, Department of Pharmacological Sciences and Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4740-243X
Katherine LansuNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA.
Alexandra R TriboNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA.
Reid H J OlsenNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA.
Tao CheNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA.
Jian JinCenter for Chemical Biology and Drug Discovery, Department of Pharmacological Sciences and Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-2387-3862
Bryan L RothNational Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC, USA. bryan_roth@med.unc.edu.ORCID http://orcid.org/0000-0002-0561-6520
University of North Carolina at Chapel Hill · USIcahn School of Medicine at Mount Sinai · US

Funding

Screening CoreU19MH082441 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CARON, MARC G., ROTH, BRYAN L. · 2007 to 2016
$15.2M
Molecular Details of Psychoactive Drug ActionsR01MH112205 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2017 to 2026
$6.1M
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIST32GM007040 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS, ROBERT A · 1985 to 2019
$6.0M
Mechanistic insights into LSD actions at 5-HT2A serotonin receptorsR37DA045657 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth · 2018 to 2026
$5.8M
Targeting and Trafficking of 5-HT2A Serotonin ReceptorsR01MH061887 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L. · 2000 to 2014
$4.5M
Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's SymptomsR01NS100930 · NINDS · DUKE UNIVERSITY · PI CARON, MARC G. · 2017 to 2021
$3.2M
Regulation of Adult Hippocampal Neurogenesis by Cholecystokinin-Expressing InterneuronsF31NS093917 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI OLSEN, REID HANS JOHNSON · 2015 to 2017
$103k
NIDA NIH HHS R37 DA045657NIGMS NIH HHS T32 GM007040NIMH NIH HHS R01 MH061887NIMH NIH HHS R01 MH112205NIMH NIH HHS U19 MH082441NINDS NIH HHS F31 NS093917NINDS NIH HHS R01 NS100930
6 · The paper itself

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) receptors modulate a variety of physiological processes ranging from perception, cognition and emotion to vascular and smooth muscle contraction, platelet aggregation, gastrointestinal function and reproduction. Drugs that interact with 5-HT receptors effectively treat diseases as diverse as migraine headaches, depression and obesity. Here we present four structures of a prototypical serotonin receptor-the human 5-HT

Indexed as

Binding SitesHumansLigandsMutagenesisProtein ConformationReceptor, Serotonin, 5-HT2BSerotonin Receptor AgonistsSignal TransductionLigandsReceptor, Serotonin, 5-HT2BSerotonin Receptor Agonists

Identifiers

PMID30127358
PMCPMC6237183
OpenAlexW2982809992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.